Aolvxin

Aolvxin was founded in February 2012 and successfully listed on the New Third Board in August 2017 (stock code 871920). Adhering to the vision of "integrating medicine and engineering technology, creating medical devices, and improving the quality of human life," the company has built a nationally leading medical device medical-engineering integration innovation and transformation platform, with a total operating area of over 38,000 square meters, a team of over 400 people, and R&D technical personnel accounting for approximately 70%.
The company has undertaken a special project of the Ministry of Science and Technology's "National Key R&D Program" and has been recognized as a Hubei Provincial Engineering Research Center, a Hubei Provincial Enterprise Technology Center, a Hubei Provincial listed "Golden Seed" enterprise, a Hubei Provincial pilot-scale testing base for minimally invasive precision surgical medical devices, a Hubei Provincial specialized, refined, distinctive and innovative "little giant" enterprise, the Wuhan Minimally Invasive Medical Device Technology Achievement Transformation Center, and a public service platform of the Wuhan National Bioindustry Base.
As of now, the company has collaborated with top clinical experts to develop nearly 400 innovative medical devices, of which 4 projects have been approved to enter the national green channel for innovative medical devices, and 1 achievement won the First Prize for Technological Invention of the Hubei Provincial Science and Technology Award.